Physician
Oncology
Dr. William N. William Jr., MD
|
|
Give Review
William William practices Oncology. William N. William Jr., MD is a published doctor. He has 52 papers published. The most current publication "Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes."
Publications
- Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories.
- Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy.
- A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
- New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development.
- Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma.
- Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
- Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives.
- Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry.
- Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3.
- A Novel Target for Oral Cancer Chemoprevention? Notch Quite, Yet….
- Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
- Sleep-Related Breathing Disorders in Patients With Tumors in the Head and Neck Region.
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
- A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer.
- Optimizing Surrogate End Points for Preoperative Systemic Therapies in Non-Small Cell Lung Cancers.
- Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention.
- Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients.
- p16 expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck.
- HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
- The role of systemic treatment before, during, and after definitive treatment.
- Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.
- Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small-Cell Lung Cancer after Neoadjuvant C...
- Novel strategies for the treatment of small-cell lung carcinoma.
- High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.
- Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
- Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
- Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
- Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
- Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
- Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data.
- A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
- Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
- Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.
- High-dose fenretinide in oral leukoplakia.
- Cyclin D1 and cancer development in laryngeal premalignancy patients.
- Pilot randomized phase II study of celecoxib in oral premalignant lesions.
- Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
- Necrotizing fasciitis as a late complication of multimodal treatment for locally advanced head and neck cancer: a case report.
- The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.
- Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
- Pivotal role of leptin in insulin effects.
- Leptin increases glucose transport and utilization in skeletal muscle in vitro.
- Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes.
- Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation.
- Modulation of insulin secretion by leptin.
- Acute effects of leptin on glucose metabolism of in situ rat perfused livers and isolated hepatocytes.
- Leptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes.
- The response of skeletal muscle to leptin.
- Leptin controls the fate of fatty acids in isolated rat white adipocytes.
- Molecular targets for cancer chemoprevention.
- Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.
Schools
Universidade De Sao Paulo Faculdade De Medicina
Doctors Specialties
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Benesys
- Blue Card PPO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Old Surety Life Insurance CompanyMedicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
University of Sao Paulo Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center -
Baylor St. Luke's Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Harry R. Price, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Khaled W. Jabboury, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vassiliki A. Papadimitrakopoulou, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Scott M. Lippman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Julie A. Ellerhorst, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Daniel E. Epner II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick Hwu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miloslav I. Beran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shan Guo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aaron J. Schueneman, MD
This Doctor is OpenDoctor Recommended.
|